TY  - JOUR
AU  - Pérez de Isla, Leopoldo
AU  - Ray, Kausik K
AU  - Watts, Gerald F
AU  - Santos, Raul D
AU  - Alonso, Rodrigo
AU  - Muñiz-Grijalvo, Ovidio
AU  - Diaz-Diaz, Jose Luis
AU  - Badimon, Lina
AU  - Catapano, Alberico L
AU  - Mata, Pedro
PY  - 2019
DO  - 10.1016/j.atherosclerosis.2019.05.003
UR  - http://hdl.handle.net/10668/13978
T2  - Atherosclerosis
AB  - Patients with familial hypercholesterolaemia (FH) may require proprotein convertase subtilisin/kexin-type 9 (PCSK9) mAb as add-on therapy to achieve LDL-cholesterol (LDL-C) goals. However, the current cost of these therapies means that choosing...
LA  - en
KW  - CTT
KW  - Cardiovascular risk assessment
KW  - Familial hypercholesterolemia
KW  - NNT
KW  - PCSK9 mAb
KW  - SAFEHEART
KW  - Antibodies, Monoclonal
KW  - Cholesterol, LDL
KW  - Heterozygote
KW  - Humans
KW  - Hyperlipoproteinemia Type II
KW  - Immunologic Factors
KW  - Mathematical Concepts
KW  - Proprotein Convertase 9
KW  - Prospective Studies
KW  - Risk Assessment
TI  - Potential utility of the SAFEHEART risk equation for rationalising the use of PCSK9 monoclonal antibodies in adults with heterozygous familial hypercholesterolemia.
TY  - research article
VL  - 286
ER  -